British biotech company Silence Therapeutics (AIM: SLN) has paid £7.8 million ($9.6 million) to acquire an 8.4% stake in Arrowhead Pharmaceuticals (Nasdaq: ARWR).
US-based Arrowhead gained almost a quarter on the Nasdaq before close of trading on Friday. Shares in Silence Therapeutics rose 4% by noon on Monday.
Both companies are focussed on developing clinical-stage RNA therapeutics.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze